Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
This study is currently recruiting participants.
Verified March 2013 by Seattle Genetics, Inc.
Study NCT01166490   Information provided by Seattle Genetics, Inc.

First Received on July 19, 2010.   Last Updated on March 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastric Neoplasms
Pancreatic Neoplasms
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Pancreatic Diseases
Stomach Diseases
Interventions listed in this trial
ASG-5ME
Sponsors listed in this trial
Seattle Genetics, Inc.
Agensys, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services